160 related articles for article (PubMed ID: 35514050)
1. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort.
Ximenez JP; Elias ABR; Nardotto GHB; Barroso PF; Bollela VR; Lanchote VL; Suarez-Kurtz G
Br J Clin Pharmacol; 2022 Oct; 88(10):4585-4594. PubMed ID: 35514050
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
[TBL] [Abstract][Full Text] [Related]
3. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
Reay R; Dandara C; Viljoen M; Rheeders M
OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico.
Ortíz-Rodríguez MA; Oaxaca-Navarro J; Patiño-Camacho SI; García-Jiménez S; Déciga-Campos M; Martínez-Salazar MF
Pharmazie; 2022 Jun; 77(6):191-195. PubMed ID: 35751161
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
Soeria-Atmadja S; Österberg E; Gustafsson LL; Dahl ML; Eriksen J; Rubin J; Navér L
PLoS One; 2017; 12(9):e0181316. PubMed ID: 28886044
[TBL] [Abstract][Full Text] [Related]
7. Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.
Chala A; Kitabi EN; Ahmed JH; Tadesse BT; Chaka TE; Makonnen E; Aklillu E
CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):783-794. PubMed ID: 36840416
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.
Olagunju A; Siccardi M; Amara A; Jevtovic D; Kusic J; Owen A; Dragovic G
Ther Drug Monit; 2014 Dec; 36(6):734-8. PubMed ID: 24831655
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
[TBL] [Abstract][Full Text] [Related]
11. Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.
Nwogu JN; Gandhi M; Owen A; Khoo SH; Taiwo B; Olagunju A; Berzins B; Okochi H; Tallerico R; Robertson K; Babalola CP
AIDS; 2021 Oct; 35(12):1919-1927. PubMed ID: 34115651
[TBL] [Abstract][Full Text] [Related]
12. Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.
Bordin Andriguetti N; Van Schalkwyk HK; Barratt DT; Tucci J; Pumuye P; Somogyi AA
Clin Transl Sci; 2021 Nov; 14(6):2521-2531. PubMed ID: 34415664
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
Vujkovic M; Bellamy SL; Zuppa AF; Gastonguay M; Moorthy GS; Ratshaa BR; Han X; Steenhoff AP; Mosepele M; Strom BL; Aplenc R; Bisson GP; Gross R
J Acquir Immune Defic Syndr; 2017 Aug; 75(4):488-491. PubMed ID: 28481785
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
[TBL] [Abstract][Full Text] [Related]
18. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
[TBL] [Abstract][Full Text] [Related]
19. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
[TBL] [Abstract][Full Text] [Related]
20. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
Paganotti GM; Russo G; Sobze MS; Mayaka GB; Muthoga CW; Tawe L; Martinelli A; Romano R; Vullo V
Infect Genet Evol; 2015 Oct; 35():122-6. PubMed ID: 26247717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
